Sustained remission in relapsed/refractory diffuse large B cell lymphoma following Glofitamab discontinuation due to JC virus reactivation: balancing efficacy and infectious risk.
1/5 보강
The therapeutic landscape for relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) is expanding, with bispecific antibodies emerging as key treatment strategies.
APA
Marinoni M, De Marchi L, et al. (2026). Sustained remission in relapsed/refractory diffuse large B cell lymphoma following Glofitamab discontinuation due to JC virus reactivation: balancing efficacy and infectious risk.. Current research in translational medicine, 74(1), 103549. https://doi.org/10.1016/j.retram.2025.103549
MLA
Marinoni M, et al.. "Sustained remission in relapsed/refractory diffuse large B cell lymphoma following Glofitamab discontinuation due to JC virus reactivation: balancing efficacy and infectious risk.." Current research in translational medicine, vol. 74, no. 1, 2026, pp. 103549.
PMID
41259996 ↗
Abstract 한글 요약
The therapeutic landscape for relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) is expanding, with bispecific antibodies emerging as key treatment strategies. These drugs have demonstrated high efficacy in this setting of patient, but leading to prolonged immunosuppression, exposing patients to a high risk of infections. We describe a R/R DLBCL patient achieving complete remission (CR) with glofitamab, although discontinued due to JC virus reactivation. Nineteen months post-treatment, the patient remains in CR, with declining viral copies and no evidence of neurological complications. The patient also has a history of chronic myeloid leukemia (CML), currently in treatment free remission (TFR). This is an example of durable DLBCL remission despite abbreviated glofitamab therapy, while highlighting challenges in balancing immunotherapy efficacy with opportunistic infection risks.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.